Publications
5539 Results
- Journal / Conference
- Proc of the American Society of Clinical Oncology 23:713 (#7527)
- Year
- 2004
- Research Committee(s)
- Melanoma
- Study Number(s)
- S0026
Interferon Alpha-2b and thalidomide in previously treated patients with disseminated malignant melanoma: SWOG 0026
- Journal / Conference
- Proc of the American Society of Clinial Oncology 23:489 (#5512)
- Year
- 2004
- Research Committee(s)
- Head and Neck
- Study Number(s)
- S0007
A phase II evaluation of a 3-hour infusion of paclitaxel (P), cisplatin (CDDP) & 5-fluorouracil (5FU) in patients with advanced or recurrent squamous cell carcinoma of the head and neck (SCCHN). A Southwest Oncology Group (SWOG) study
- Journal / Conference
- Proc of the American Society of Clinical Oncology 23:627 (#7056)
- Year
- 2004
- Research Committee(s)
- Lung
- Study Number(s)
- S0027
Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: a SWOG phase II trial (S0027)
- Journal / Conference
- Proc of the American Society of Clinical Oncology 23:815 (#9005)
- Year
- 2004
- Research Committee(s)
- Sarcoma
- Study Number(s)
- S0033
Dose effect of imatinib (IM) in patients (pts) with metastatic GIST-phase III sarcoma group study S0033
- Journal / Conference
- Proc of the American Society of Clinical Oncology 23:315 (4012)
- Year
- 2004
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S0107
A phase II trial of epothilone B analogue BMS-247550 (NSC# 710428) in patients with advanced pancreas cancer: a Southwest Oncology Group study
- Journal / Conference
- Proc of the American Society of Clinical Oncology 23:383 (#4510)
- Year
- 2004
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0111
Epothilone B (Epo-B) analogue BMS-247550 (NSC# 710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). a Southwest Oncology Group study (S0111)
- Journal / Conference
- Proc of the American Society of Clinical Oncology 23:618 (#7014)
- Year
- 2004
- Research Committee(s)
- Lung
- Study Number(s)
- S0126
Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126.
- Journal / Conference
- Proc of the American Society of Clincial Oncology 23:196 (#3007)
- Year
- 2004
- Research Committee(s)
- Lung
- Study Number(s)
- S0218
Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM)
- Journal / Conference
- Journal of Urology 171(Suppl 4):72(#273)
- Year
- 2004
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-8507
Timing of recurrence and outcomes following induction BCG for high risk Ta, T1 bladder cancer - a Southwest Oncology Group Trial
- Journal / Conference
- New England Journal of Medicine 351(15):1513-1520
- Year
- 2004
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S9916